Institut für klinische Forschung Pneumologie
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
The Institut für klinische Forschung Pneumologie in Frankfurt is conducting respiratory research focused on asthma, with studies aimed at improving symptom control, lung function, and overall treatment effectiveness in people whose disease remains difficult to manage.
- Severe and inadequately controlled asthma
- Mild to moderate asthma
- Evaluating new inhaled treatment options for better breathing outcomes
These trials explore whether newer inhaler-based therapies can help reduce exacerbations and improve day-to-day respiratory stability for patients with persistent asthma symptoms.
Virus Diseases
The site is also involved in infectious disease research, including studies in COVID-19 for people at higher risk of becoming seriously ill. This work focuses on finding treatments that may help prevent disease worsening in nonhospitalized patients.
- COVID-19 at high risk of progression to severe illness
- Testing an antiviral approach against placebo
- Supporting early treatment strategies for viral illness
By examining treatment effectiveness early in the course of infection, the research aims to improve outcomes for vulnerable patients before hospitalization becomes necessary.
Asthma Treatment Equivalence and Lung Function
Another key area of research at this health care site centers on comparing established asthma therapies and assessing whether different inhaled formulations perform similarly in patients with controlled or partly controlled disease.
- Comparing inhaled therapies for mild to moderate asthma
- Measuring changes in lung function
- Evaluating therapeutic equivalence of new inhaler formulations
This line of research helps determine whether alternative inhaled medicines can provide comparable respiratory benefits while maintaining effective control of symptoms.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut für klinische Forschung Pneumologie
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Assessment of Budesonide, Glycopyrronium, and Formoterol Fumarate MDI in Severe Asthma Uncontrolled by Standard Therapy | AstraZeneca AB | Phase III | Not Recruiting | Apr 2021 | Mar 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Formoterol Fumarate Dihydrate | 2 | Unknown | 2021-04-25 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.